Boston Family Office LLC Acquires Shares of 33,893 Zoetis Inc. (NYSE:ZTS)

Boston Family Office LLC acquired a new position in shares of Zoetis Inc. (NYSE:ZTS) during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm acquired 33,893 shares of the company’s stock, valued at approximately $6,622,000.

A number of other hedge funds and other institutional investors have also made changes to their positions in the company. Mizuho Securities USA LLC increased its holdings in shares of Zoetis by 13,726.9% in the 3rd quarter. Mizuho Securities USA LLC now owns 4,865,000 shares of the company’s stock valued at $950,524,000 after acquiring an additional 4,829,815 shares during the period. Sarasin & Partners LLP increased its stake in Zoetis by 546.3% in the second quarter. Sarasin & Partners LLP now owns 2,253,590 shares of the company’s stock valued at $390,682,000 after purchasing an additional 1,904,899 shares during the period. Swedbank AB purchased a new stake in shares of Zoetis in the first quarter valued at about $210,815,000. International Assets Investment Management LLC boosted its stake in shares of Zoetis by 41,235.7% during the third quarter. International Assets Investment Management LLC now owns 939,974 shares of the company’s stock worth $183,652,000 after buying an additional 937,700 shares during the period. Finally, Marshall Wace LLP grew its holdings in shares of Zoetis by 7,608.6% during the second quarter. Marshall Wace LLP now owns 835,684 shares of the company’s stock worth $144,874,000 after buying an additional 824,843 shares during the last quarter. Institutional investors and hedge funds own 92.80% of the company’s stock.

Zoetis Trading Up 0.1 %

Shares of ZTS opened at $176.96 on Monday. The company has a debt-to-equity ratio of 1.26, a current ratio of 3.69 and a quick ratio of 2.27. Zoetis Inc. has a 1-year low of $144.80 and a 1-year high of $201.92. The stock has a market cap of $79.84 billion, a price-to-earnings ratio of 33.26, a price-to-earnings-growth ratio of 2.71 and a beta of 0.90. The firm has a 50 day simple moving average of $185.62 and a 200-day simple moving average of $180.72.

Zoetis (NYSE:ZTS) last released its quarterly earnings results on Monday, November 4th. The company reported $1.58 earnings per share for the quarter, topping the consensus estimate of $1.46 by $0.12. Zoetis had a return on equity of 51.98% and a net margin of 26.55%. The company had revenue of $2.40 billion during the quarter, compared to the consensus estimate of $2.29 billion. During the same quarter last year, the business posted $1.36 earnings per share. Zoetis’s revenue was up 11.6% compared to the same quarter last year. Equities analysts forecast that Zoetis Inc. will post 5.9 EPS for the current fiscal year.

Zoetis Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Tuesday, December 3rd. Shareholders of record on Thursday, October 31st will be paid a dividend of $0.432 per share. The ex-dividend date of this dividend is Thursday, October 31st. This represents a $1.73 annualized dividend and a dividend yield of 0.98%. Zoetis’s dividend payout ratio is currently 32.52%.

Analyst Ratings Changes

Several analysts have commented on the company. Piper Sandler upped their price objective on Zoetis from $195.00 to $210.00 and gave the company an “overweight” rating in a research note on Wednesday, August 14th. Argus raised Zoetis to a “strong-buy” rating in a report on Friday, August 9th. JPMorgan Chase & Co. boosted their price objective on shares of Zoetis from $225.00 to $230.00 and gave the company an “overweight” rating in a research note on Friday, October 11th. BTIG Research raised their target price on shares of Zoetis from $220.00 to $225.00 and gave the stock a “buy” rating in a research note on Monday, August 12th. Finally, Stifel Nicolaus upped their price objective on Zoetis from $200.00 to $210.00 and gave the stock a “buy” rating in a report on Wednesday, September 18th. Ten investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Buy” and an average price target of $221.44.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.